SG Americas Securities LLC Increases Stock Position in Denali Therapeutics Inc. $DNLI

SG Americas Securities LLC boosted its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) by 291.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 149,592 shares of the company’s stock after buying an additional 111,391 shares during the period. SG Americas Securities LLC owned approximately 0.10% of Denali Therapeutics worth $2,470,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Headlands Technologies LLC purchased a new stake in shares of Denali Therapeutics during the 2nd quarter valued at $26,000. Johnson Financial Group Inc. purchased a new stake in Denali Therapeutics during the 3rd quarter valued at about $29,000. State of Wyoming bought a new position in Denali Therapeutics during the 2nd quarter worth approximately $29,000. Quarry LP purchased a new position in Denali Therapeutics in the 3rd quarter worth approximately $64,000. Finally, Intrust Bank NA purchased a new position in Denali Therapeutics in the 3rd quarter worth approximately $154,000. Institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Price Performance

Shares of NASDAQ:DNLI opened at $20.65 on Friday. The firm has a market capitalization of $3.27 billion, a P/E ratio of -6.95 and a beta of 1.10. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.16 and a current ratio of 9.16. The stock has a 50 day moving average price of $20.49 and a 200-day moving average price of $18.05. Denali Therapeutics Inc. has a 52-week low of $10.57 and a 52-week high of $23.77.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.02. During the same period in the prior year, the business earned ($0.67) EPS. As a group, equities research analysts anticipate that Denali Therapeutics Inc. will post -2.71 EPS for the current fiscal year.

Insider Transactions at Denali Therapeutics

In other news, CEO Ryan J. Watts sold 35,198 shares of the company’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total value of $580,767.00. Following the sale, the chief executive officer directly owned 296,833 shares of the company’s stock, valued at $4,897,744.50. This represents a 10.60% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Alexander O. Schuth sold 17,218 shares of the stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total transaction of $284,097.00. Following the completion of the transaction, the insider owned 282,828 shares of the company’s stock, valued at approximately $4,666,662. The trade was a 5.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 12.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages have recently issued reports on DNLI. Wedbush cut their target price on shares of Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating on the stock in a report on Thursday, December 11th. The Goldman Sachs Group raised their price target on shares of Denali Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. Stifel Nicolaus boosted their price objective on shares of Denali Therapeutics from $34.00 to $41.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. HC Wainwright raised their target price on Denali Therapeutics from $32.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. Finally, UBS Group initiated coverage on Denali Therapeutics in a report on Wednesday, January 7th. They set a “buy” rating on the stock. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $34.82.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.